Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...

Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...

Resmed RMD has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S.

Personal Therapy Assistant feature for AirSense 11 users, seen here within the myAir app SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ResMed, a global leader in digital health and sleep apnea ...

Sleep therapy giant ResMed said its first quarter revenue increased by 6 per cent to $US380 million ($433.84 million), which was buoyed by recent product launches but ...

After Philips issued a recall in mid-June of nearly two dozen models of its continuous and noncontinuous ventilators, ResMed has eagerly stepped up to fill in the market gap left by Philips’ absence.

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) — ResMed, a global leader in digital health and sleep apnea treatment, (NYSE: RMD, ASX: RMD) today launched AirSense 11, available first in the U.S., the ...